Global Uterine Cancer Treatment Market - 2025-2033
Global Uterine Cancer Treatment Market - Industry Outlook & Trends
The global uterine cancer treatment market size reached US$ 23,633.46 Million in 2024 and is expected to reach US$ 39,007.22 Million by 2033, growing at a CAGR of 5.4% during the forecast period 2025-2033.
Uterine cancer refers to malignancies that develop in the uterus (womb), primarily affecting women who have gone through menopause. This disease is characterized by abnormal cell growth within the uterine tissues and is often linked to elevated estrogen levels as a primary risk factor.
The industry outlook remains positive, with a steady increase in demand for advanced therapies. Key industry trends include a shift toward minimally invasive surgical techniques, the integration of targeted therapy and immunotherapy for recurrent and advanced cases, and a growing emphasis on personalized medicine. Trends also show that the adoption of robotic surgery and molecular diagnostics is improving patient outcomes and expanding the scope of treatment.
Key drivers of market growth include the increasing global incidence of uterine cancers, particularly linked to rising obesity rates and aging populations. Opportunities abound in the development of novel targeted therapies and immunotherapies, especially for uterine sarcoma, where unmet medical needs remain significant. Expansion of healthcare infrastructure in emerging markets and supportive government initiatives further broaden the market’s scope.
Global Uterine Cancer Treatment Market Dynamics: Drivers & Restraints
Rising Incidence of Uterine Cancer
The growing number of new uterine cancer cases worldwide is a significant driver of the global uterine cancer treatment market. According to National Institutes of Health data, in 2023, the rate of new uterine cancer cases is 28.3 per 100,000 women per year, while the death rate stands at 5.3 per 100,000 women per year (age-adjusted, based on 2018–2022 incidence and 2019–2023 mortality data). Additionally, the lifetime risk for women developing uterine cancer is approximately 3.1%, meaning about 1 in 32 women will be diagnosed with this disease during their lifetime.
The rising incidence of uterine cancer directly increases the number of patients need care, thereby expanding the market for all types of uterine cancer treatments. As more women are diagnosed with uterine cancer each year, the demand for all categories of treatment- chemotherapy, hormone therapy, targeted therapy, immunotherapy, radiation, surgery, and supportive care- rises proportionally. This trend encourages innovation, investment, and expansion across the entire spectrum of therapies and services, making it one of the most important drivers of market growth.
Side Effects and Toxicity Associated with the Treatment
One of the significant challenges restraining the growth of the global uterine cancer treatment market is the side effects and toxicity associated with various treatment modalities. Treatments such as chemotherapy, hormone therapy, targeted therapy, immunotherapy, radiation, and surgery, while effective in controlling or eliminating cancer, often cause adverse effects that can severely impact patients’ quality of life and limit their ability to continue therapy.
Chemotherapy drugs like paclitaxel, carboplatin, and doxorubicin, which are commonly used in uterine cancer treatment, are known for their systemic toxicity. Patients frequently experience side effects such as nausea, vomiting, hair loss, fatigue, myelosuppression (leading to increased infection risk), and neuropathy.
Hormone therapies, including agents like medroxyprogesterone acetate and tamoxifen, can cause weight gain, blood clots, hot flashes, and other hormonal imbalances. While targeted therapies and immunotherapies represent promising advances, they are not without their side effects. Targeted agents such as lenvatinib and bevacizumab can cause hypertension, proteinuria, and gastrointestinal issues. These toxicities often necessitate dose reductions, treatment delays, or discontinuation, thereby limiting the overall effectiveness of therapy.
Global Uterine Cancer Treatment Market - Epidemiology Analysis
The rising incidence of uterine cancer is creating significant challenges for global healthcare systems. According to DataM Intelligence estimates, the number of prevalent uterine cancer cases is projected to grow from approximately 0.69 million in 2024 to 0.76 million by 2030. This upward trend underscores the urgent need for effective interventions, especially in regions where uterine cancer rates are highest, such as developing countries and among high-risk populations.
While early detection, improved treatment options, and advancements in healthcare infrastructure have led to better outcomes in developed nations, substantial challenges persist in low- and middle-income countries. These include limited access to timely diagnosis, fewer available treatment modalities, and disparities in healthcare resources, which contribute to poorer prognoses and higher mortality rates.
Global Uterine Cancer Treatment Market - Segment Analysis
The global uterine cancer treatment market is segmented based on cancer type, treatment type, and region.
Treatment Type:
The chemotherapy segment was valued at US$ 334.55 million in 2024 and is estimated to reach US$ 715.89 million by 2033, growing at a CAGR of 7.8% during the forecast period from 2025-2033
Chemotherapy involves the use of cytotoxic drugs that target rapidly dividing cancer cells, and it is often administered as a combination regimen to maximize effectiveness. Chemotherapy remains a cornerstone in the treatment of uterine cancer, especially for advanced, recurrent, or metastatic disease. It involves the use of cytotoxic drugs that kill rapidly dividing cancer cells. In the global market, chemotherapy is widely adopted due to its proven effectiveness, established protocols, and availability of both branded and generic drugs.
Chemotherapy can be administered as a single agent or, more commonly, in combination regimens to enhance effectiveness and overcome resistance. It remains a cornerstone of treatment, especially for advanced, recurrent, or metastatic uterine cancer. The most commonly used agents in uterine cancer include paclitaxel, carboplatin, cisplatin, doxorubicin, liposomal doxorubicin, bevacizumab, docetaxel, gemcitabine, and others.
Additionally, key players in the industry and their product launches & approvals will drive this segment's growth. For instance, in August 2024, GSK plc announced that the US Food and Drug Administration (FDA) had approved Jemperli (dostarlimab) to be used in a new treatment regimen for adult patients with primary advanced or recurrent endometrial cancer. The approved regimen consists of Jemperli administered in combination with the chemotherapy drugs carboplatin and paclitaxel, followed by Jemperli as a single-agent maintenance therapy. This approval represents an important advancement in treatment options for patients with advanced or recurrent endometrial cancer.
Global Uterine Cancer Treatment Market - Geographical Analysis
The North America uterine cancer treatment market was valued at US$ 11,257.95 million in 2024 and is estimated to reach US$ 24,282.77 million by 2033, growing at a CAGR of 7.9% during the forecast period from 2025-2033
The number of new uterine cancer cases is steadily increasing in North America, driven by factors such as an aging population, obesity, and lifestyle changes. According to the American Cancer Society, uterine cancer is the most common gynecologic malignancy in the U.S., resulting in higher demand for all treatment modalities.
According to the American Cancer Society’s projections for 2025, approximately 69,120 new cases of uterine cancer are expected to be diagnosed in the United States. Additionally, about 13,860 women are anticipated to die from cancers of the uterus. These figures include both endometrial cancers and uterine sarcomas. Since uterine sarcomas account for up to 10% of all uterine cancer cases, the actual numbers for endometrial cancer alone are slightly lower than these estimates.
Significant progress in chemotherapy, targeted therapy, and immunotherapy (such as pembrolizumab and dostarlimab) has expanded the range of effective treatments. New drug approvals and combination regimens are improving survival outcomes and expanding the market.
For instance, in June 2024, the U.S. Food and Drug Administration (FDA) approved a new treatment regimen for adult patients with primary advanced or recurrent endometrial carcinoma, a type of uterine cancer. This regimen combines pembrolizumab (Keytruda, Merck), an immunotherapy drug, with the chemotherapy agents carboplatin and paclitaxel. Patients first receive this combination therapy to target and reduce the cancer, followed by maintenance treatment with pembrolizumab alone.
The Asia-Pacific uterine cancer treatment market was valued at US$ 7,014.73 million in 2024 and is estimated to reach US$ 15,607.68 million by 2033, growing at a CAGR of 8.2% during the forecast period from 2025-2033
The Asia-Pacific uterine cancer treatment market is projected to witness robust growth over the forecast period, driven by rising cancer awareness, increasing healthcare expenditure, and improvements in diagnostic infrastructure.
Countries like Japan, with their advanced healthcare systems and aging populations, are at the forefront of this regional expansion. Japan is a major contributor to the Asia-Pacific uterine cancer treatment market, due to its advanced healthcare system, robust research infrastructure, and high adoption of innovative therapies. Japan’s aging population and proactive screening programs further drive demand for effective uterine cancer treatments.
Additionally, government initiatives to support cancer research and the growing presence of international pharmaceutical companies in the region are further accelerating development. Other key drivers in the Asia-Pacific region include increasing access to cancer screening programs, a rising prevalence of obesity, and expanding health insurance coverage, especially in emerging markets like India and Southeast Asia.
Global Uterine Cancer Treatment Market - Competitive Landscape (Major Players)
Top companies in the uterine cancer treatment market include Bristol-Myers Squibb Company, Pfizer Inc., Janssen Pharmaceuticals (Johnson & Johnson), F. Hoffmann-La Roche Ltd, Sanofi, Eli Lilly Services Inc, Novartis AG, AstraZeneca, Eisai Inc., GSK Plc, and Merck & Co., Inc., among others.
Global Uterine Cancer Treatment Market - Competitive Landscape (Emerging Players)
Emerging players in the uterine cancer treatment market include Antiva Biosciences, Eisai Co., Ltd., Kineta, IMMVIRA CO., LTD, Shanghai Henlius Biotech, Inc., and Iovance Biotherapeutics, Inc. and among others.
Global Uterine Cancer Treatment Market - Key Developments
Target Audience 2024
The global uterine cancer treatment market size reached US$ 23,633.46 Million in 2024 and is expected to reach US$ 39,007.22 Million by 2033, growing at a CAGR of 5.4% during the forecast period 2025-2033.
Uterine cancer refers to malignancies that develop in the uterus (womb), primarily affecting women who have gone through menopause. This disease is characterized by abnormal cell growth within the uterine tissues and is often linked to elevated estrogen levels as a primary risk factor.
The industry outlook remains positive, with a steady increase in demand for advanced therapies. Key industry trends include a shift toward minimally invasive surgical techniques, the integration of targeted therapy and immunotherapy for recurrent and advanced cases, and a growing emphasis on personalized medicine. Trends also show that the adoption of robotic surgery and molecular diagnostics is improving patient outcomes and expanding the scope of treatment.
Key drivers of market growth include the increasing global incidence of uterine cancers, particularly linked to rising obesity rates and aging populations. Opportunities abound in the development of novel targeted therapies and immunotherapies, especially for uterine sarcoma, where unmet medical needs remain significant. Expansion of healthcare infrastructure in emerging markets and supportive government initiatives further broaden the market’s scope.
Global Uterine Cancer Treatment Market Dynamics: Drivers & Restraints
Rising Incidence of Uterine Cancer
The growing number of new uterine cancer cases worldwide is a significant driver of the global uterine cancer treatment market. According to National Institutes of Health data, in 2023, the rate of new uterine cancer cases is 28.3 per 100,000 women per year, while the death rate stands at 5.3 per 100,000 women per year (age-adjusted, based on 2018–2022 incidence and 2019–2023 mortality data). Additionally, the lifetime risk for women developing uterine cancer is approximately 3.1%, meaning about 1 in 32 women will be diagnosed with this disease during their lifetime.
The rising incidence of uterine cancer directly increases the number of patients need care, thereby expanding the market for all types of uterine cancer treatments. As more women are diagnosed with uterine cancer each year, the demand for all categories of treatment- chemotherapy, hormone therapy, targeted therapy, immunotherapy, radiation, surgery, and supportive care- rises proportionally. This trend encourages innovation, investment, and expansion across the entire spectrum of therapies and services, making it one of the most important drivers of market growth.
Side Effects and Toxicity Associated with the Treatment
One of the significant challenges restraining the growth of the global uterine cancer treatment market is the side effects and toxicity associated with various treatment modalities. Treatments such as chemotherapy, hormone therapy, targeted therapy, immunotherapy, radiation, and surgery, while effective in controlling or eliminating cancer, often cause adverse effects that can severely impact patients’ quality of life and limit their ability to continue therapy.
Chemotherapy drugs like paclitaxel, carboplatin, and doxorubicin, which are commonly used in uterine cancer treatment, are known for their systemic toxicity. Patients frequently experience side effects such as nausea, vomiting, hair loss, fatigue, myelosuppression (leading to increased infection risk), and neuropathy.
Hormone therapies, including agents like medroxyprogesterone acetate and tamoxifen, can cause weight gain, blood clots, hot flashes, and other hormonal imbalances. While targeted therapies and immunotherapies represent promising advances, they are not without their side effects. Targeted agents such as lenvatinib and bevacizumab can cause hypertension, proteinuria, and gastrointestinal issues. These toxicities often necessitate dose reductions, treatment delays, or discontinuation, thereby limiting the overall effectiveness of therapy.
Global Uterine Cancer Treatment Market - Epidemiology Analysis
The rising incidence of uterine cancer is creating significant challenges for global healthcare systems. According to DataM Intelligence estimates, the number of prevalent uterine cancer cases is projected to grow from approximately 0.69 million in 2024 to 0.76 million by 2030. This upward trend underscores the urgent need for effective interventions, especially in regions where uterine cancer rates are highest, such as developing countries and among high-risk populations.
While early detection, improved treatment options, and advancements in healthcare infrastructure have led to better outcomes in developed nations, substantial challenges persist in low- and middle-income countries. These include limited access to timely diagnosis, fewer available treatment modalities, and disparities in healthcare resources, which contribute to poorer prognoses and higher mortality rates.
Global Uterine Cancer Treatment Market - Segment Analysis
The global uterine cancer treatment market is segmented based on cancer type, treatment type, and region.
Treatment Type:
The chemotherapy segment was valued at US$ 334.55 million in 2024 and is estimated to reach US$ 715.89 million by 2033, growing at a CAGR of 7.8% during the forecast period from 2025-2033
Chemotherapy involves the use of cytotoxic drugs that target rapidly dividing cancer cells, and it is often administered as a combination regimen to maximize effectiveness. Chemotherapy remains a cornerstone in the treatment of uterine cancer, especially for advanced, recurrent, or metastatic disease. It involves the use of cytotoxic drugs that kill rapidly dividing cancer cells. In the global market, chemotherapy is widely adopted due to its proven effectiveness, established protocols, and availability of both branded and generic drugs.
Chemotherapy can be administered as a single agent or, more commonly, in combination regimens to enhance effectiveness and overcome resistance. It remains a cornerstone of treatment, especially for advanced, recurrent, or metastatic uterine cancer. The most commonly used agents in uterine cancer include paclitaxel, carboplatin, cisplatin, doxorubicin, liposomal doxorubicin, bevacizumab, docetaxel, gemcitabine, and others.
Additionally, key players in the industry and their product launches & approvals will drive this segment's growth. For instance, in August 2024, GSK plc announced that the US Food and Drug Administration (FDA) had approved Jemperli (dostarlimab) to be used in a new treatment regimen for adult patients with primary advanced or recurrent endometrial cancer. The approved regimen consists of Jemperli administered in combination with the chemotherapy drugs carboplatin and paclitaxel, followed by Jemperli as a single-agent maintenance therapy. This approval represents an important advancement in treatment options for patients with advanced or recurrent endometrial cancer.
Global Uterine Cancer Treatment Market - Geographical Analysis
The North America uterine cancer treatment market was valued at US$ 11,257.95 million in 2024 and is estimated to reach US$ 24,282.77 million by 2033, growing at a CAGR of 7.9% during the forecast period from 2025-2033
The number of new uterine cancer cases is steadily increasing in North America, driven by factors such as an aging population, obesity, and lifestyle changes. According to the American Cancer Society, uterine cancer is the most common gynecologic malignancy in the U.S., resulting in higher demand for all treatment modalities.
According to the American Cancer Society’s projections for 2025, approximately 69,120 new cases of uterine cancer are expected to be diagnosed in the United States. Additionally, about 13,860 women are anticipated to die from cancers of the uterus. These figures include both endometrial cancers and uterine sarcomas. Since uterine sarcomas account for up to 10% of all uterine cancer cases, the actual numbers for endometrial cancer alone are slightly lower than these estimates.
Significant progress in chemotherapy, targeted therapy, and immunotherapy (such as pembrolizumab and dostarlimab) has expanded the range of effective treatments. New drug approvals and combination regimens are improving survival outcomes and expanding the market.
For instance, in June 2024, the U.S. Food and Drug Administration (FDA) approved a new treatment regimen for adult patients with primary advanced or recurrent endometrial carcinoma, a type of uterine cancer. This regimen combines pembrolizumab (Keytruda, Merck), an immunotherapy drug, with the chemotherapy agents carboplatin and paclitaxel. Patients first receive this combination therapy to target and reduce the cancer, followed by maintenance treatment with pembrolizumab alone.
The Asia-Pacific uterine cancer treatment market was valued at US$ 7,014.73 million in 2024 and is estimated to reach US$ 15,607.68 million by 2033, growing at a CAGR of 8.2% during the forecast period from 2025-2033
The Asia-Pacific uterine cancer treatment market is projected to witness robust growth over the forecast period, driven by rising cancer awareness, increasing healthcare expenditure, and improvements in diagnostic infrastructure.
Countries like Japan, with their advanced healthcare systems and aging populations, are at the forefront of this regional expansion. Japan is a major contributor to the Asia-Pacific uterine cancer treatment market, due to its advanced healthcare system, robust research infrastructure, and high adoption of innovative therapies. Japan’s aging population and proactive screening programs further drive demand for effective uterine cancer treatments.
Additionally, government initiatives to support cancer research and the growing presence of international pharmaceutical companies in the region are further accelerating development. Other key drivers in the Asia-Pacific region include increasing access to cancer screening programs, a rising prevalence of obesity, and expanding health insurance coverage, especially in emerging markets like India and Southeast Asia.
Global Uterine Cancer Treatment Market - Competitive Landscape (Major Players)
Top companies in the uterine cancer treatment market include Bristol-Myers Squibb Company, Pfizer Inc., Janssen Pharmaceuticals (Johnson & Johnson), F. Hoffmann-La Roche Ltd, Sanofi, Eli Lilly Services Inc, Novartis AG, AstraZeneca, Eisai Inc., GSK Plc, and Merck & Co., Inc., among others.
Global Uterine Cancer Treatment Market - Competitive Landscape (Emerging Players)
Emerging players in the uterine cancer treatment market include Antiva Biosciences, Eisai Co., Ltd., Kineta, IMMVIRA CO., LTD, Shanghai Henlius Biotech, Inc., and Iovance Biotherapeutics, Inc. and among others.
Global Uterine Cancer Treatment Market - Key Developments
- In January 2025, GSK plc announced that the European Commission had approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) as a first-line treatment for adult patients with primary advanced or recurrent endometrial cancer requiring systemic therapy.
- In June 2024, the FDA approved Imfinzi (durvalumab), an immunotherapy agent, in combination with chemotherapy for the treatment of mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer in the United States. This approval represents a significant advancement in treatment options for this specific molecular subtype of endometrial cancer.
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by Treatment Type
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Incidence of Uterine Cancer
3.1.1.2. Advances in Targeted & Immunotherapies
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Side Effects and Toxicity Associated with the Treatment
3.1.2.2. High Cost of Treatment
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Expansion in Emerging Markets
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. UTERINE CANCER TREATMENT MARKET, BY CANCER TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Endometrial Cancer*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Uterine Sarcoma
6. UTERINE CANCER TREATMENT MARKET, BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Chemotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Paclitaxel
6.2.4. Carboplatin
6.2.5. Cisplatin
6.2.6. Doxorubicin
6.2.7. Liposomal Doxorubicin
6.2.8. Bevacizumab
6.2.9. Docetaxel
6.2.10. Gemcitabine
6.2.11. Others
6.3. Hormone Therapy
6.3.1. Medroxyprogesterone Acetate
6.3.2. Megestrol acetate
6.3.3. Letrozole
6.3.4. Anastrozole
6.3.5. Exemestane
6.3.6. Tamoxifen
6.3.7. Fulvestrant
6.3.8. Ribociclib
6.3.9. Abemaciclib
6.3.10. Others
6.4. Targeted Therapy
6.4.1. Trastuzumab (Herceptin)
6.4.2. Fam-trastuzumab deruxtecan-nxki
6.4.3. Lenvatinib
6.4.4. Bevacizumab
6.4.5. Everolimus
6.4.6. Temsirolimus
6.4.7. Cabozantinib
6.4.8. Others
6.5. Immunotherapy
6.5.1. Durvalumab
6.5.2. Avelumab
6.5.3. Pembrolizumab
6.5.4. Dostarlimab
6.5.5. Nivolumab
6.5.6. Others
6.6. Radiation Therapy
6.7. Surgery
6.8. Others
7. UTERINE CANCER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
Major Players
9.1. Bristol-Myers Squibb Company
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. Pfizer Inc.
9.3. Janssen Pharmaceuticals (Johnson & Johnson)
9.4. F. Hoffmann-La Roche Ltd
9.5. Sanofi
9.6. Eli Lilly Services Inc
9.7. Novartis AG
9.8. AstraZeneca
9.9. Eisai Inc.
9.10. GSK Plc
9.11. Merck & Co., Inc.
Emerging Players
9.12. Antiva Biosciences
9.13. Eisai Co., Ltd.
9.14. Kineta
9.15. IMMVIRA CO., LTD
9.16. Shanghai Henlius Biotech, Inc.
9.17. Iovance Biotherapeutics, Inc.
LIST NOT EXHAUSTIVE
10. ASSUMPTIONS AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by Treatment Type
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Incidence of Uterine Cancer
3.1.1.2. Advances in Targeted & Immunotherapies
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Side Effects and Toxicity Associated with the Treatment
3.1.2.2. High Cost of Treatment
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Expansion in Emerging Markets
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. UTERINE CANCER TREATMENT MARKET, BY CANCER TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Endometrial Cancer*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Uterine Sarcoma
6. UTERINE CANCER TREATMENT MARKET, BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Chemotherapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Paclitaxel
6.2.4. Carboplatin
6.2.5. Cisplatin
6.2.6. Doxorubicin
6.2.7. Liposomal Doxorubicin
6.2.8. Bevacizumab
6.2.9. Docetaxel
6.2.10. Gemcitabine
6.2.11. Others
6.3. Hormone Therapy
6.3.1. Medroxyprogesterone Acetate
6.3.2. Megestrol acetate
6.3.3. Letrozole
6.3.4. Anastrozole
6.3.5. Exemestane
6.3.6. Tamoxifen
6.3.7. Fulvestrant
6.3.8. Ribociclib
6.3.9. Abemaciclib
6.3.10. Others
6.4. Targeted Therapy
6.4.1. Trastuzumab (Herceptin)
6.4.2. Fam-trastuzumab deruxtecan-nxki
6.4.3. Lenvatinib
6.4.4. Bevacizumab
6.4.5. Everolimus
6.4.6. Temsirolimus
6.4.7. Cabozantinib
6.4.8. Others
6.5. Immunotherapy
6.5.1. Durvalumab
6.5.2. Avelumab
6.5.3. Pembrolizumab
6.5.4. Dostarlimab
6.5.5. Nivolumab
6.5.6. Others
6.6. Radiation Therapy
6.7. Surgery
6.8. Others
7. UTERINE CANCER TREATMENT MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
Major Players
9.1. Bristol-Myers Squibb Company
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. Pfizer Inc.
9.3. Janssen Pharmaceuticals (Johnson & Johnson)
9.4. F. Hoffmann-La Roche Ltd
9.5. Sanofi
9.6. Eli Lilly Services Inc
9.7. Novartis AG
9.8. AstraZeneca
9.9. Eisai Inc.
9.10. GSK Plc
9.11. Merck & Co., Inc.
Emerging Players
9.12. Antiva Biosciences
9.13. Eisai Co., Ltd.
9.14. Kineta
9.15. IMMVIRA CO., LTD
9.16. Shanghai Henlius Biotech, Inc.
9.17. Iovance Biotherapeutics, Inc.
LIST NOT EXHAUSTIVE
10. ASSUMPTIONS AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
LIST OF TABLES
Table 1 Global Uterine Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Uterine Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Uterine Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Uterine Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 6 Global Uterine Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 8 Global Uterine Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Uterine Cancer Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 10 North America Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 11 North America Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 12 North America Uterine Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 13 South America Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 14 South America Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 15 South America Uterine Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 16 Europe Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 17 Europe Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 18 Europe Uterine Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Uterine Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 22 Middle East and Africa Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 23 Middle East and Africa Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 24 Middle East and Africa Uterine Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Bristol-Myers Squibb Company: Overview
Table 26 Bristol-Myers Squibb Company: Product Portfolio
Table 27 Bristol-Myers Squibb Company: Key Developments
Table 28 Pfizer Inc.: Overview
Table 29 Pfizer Inc.: Product Portfolio
Table 30 Pfizer Inc.: Key Developments
Table 31 Janssen Pharmaceuticals (Johnson & Johnson): Overview
Table 32 Janssen Pharmaceuticals (Johnson & Johnson): Product Portfolio
Table 33 Janssen Pharmaceuticals (Johnson & Johnson): Key Developments
Table 34 F. Hoffmann-La Roche Ltd: Overview
Table 35 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 36 F. Hoffmann-La Roche Ltd: Key Developments
Table 37 Sanofi: Overview
Table 38 Sanofi: Product Portfolio
Table 39 Sanofi: Key Developments
Table 40 Eli Lilly Services Inc: Overview
Table 41 Eli Lilly Services Inc: Product Portfolio
Table 42 Eli Lilly Services Inc: Key Developments
Table 43 Novartis AG: Overview
Table 44 Novartis AG: Product Portfolio
Table 45 Novartis AG: Key Developments
Table 46 AstraZeneca: Overview
Table 47 AstraZeneca: Product Portfolio
Table 48 AstraZeneca: Key Developments
Table 49 Eisai Inc.: Overview
Table 50 Eisai Inc.: Product Portfolio
Table 51 Eisai Inc.: Key Developments
Table 52 GSK Plc: Overview
Table 53 GSK Plc: Product Portfolio
Table 54 GSK Plc: Key Developments
Table 55 Merck & Co., Inc.: Overview
Table 56 Merck & Co., Inc.: Product Portfolio
Table 57 Merck & Co., Inc.: Key Developments
Table 58 Antiva Biosciences: Overview
Table 59 Antiva Biosciences: Product Portfolio
Table 60 Antiva Biosciences: Key Developments
Table 61 Eisai Co., Ltd.: Overview
Table 62 Eisai Co., Ltd.: Product Portfolio
Table 63 Eisai Co., Ltd.: Key Developments
Table 64 Kineta: Overview
Table 65 Kineta: Product Portfolio
Table 66 Kineta: Key Developments
Table 67 IMMVIRA CO., LTD: Overview
Table 68 IMMVIRA CO., LTD: Product Portfolio
Table 69 IMMVIRA CO., LTD: Key Developments
Table 70 Shanghai Henlius Biotech, Inc.: Overview
Table 71 Shanghai Henlius Biotech, Inc.: Product Portfolio
Table 72 Shanghai Henlius Biotech, Inc.: Key Developments
Table 73 Iovance Biotherapeutics, Inc.: Overview
Table 74 Iovance Biotherapeutics, Inc.: Product Portfolio
Table 75 Iovance Biotherapeutics, Inc.: Key Developments
Table 1 Global Uterine Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Uterine Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Uterine Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Uterine Cancer Treatment Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 6 Global Uterine Cancer Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 8 Global Uterine Cancer Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Uterine Cancer Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 10 North America Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 11 North America Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 12 North America Uterine Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 13 South America Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 14 South America Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 15 South America Uterine Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 16 Europe Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 17 Europe Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 18 Europe Uterine Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Uterine Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 22 Middle East and Africa Uterine Cancer Treatment Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 23 Middle East and Africa Uterine Cancer Treatment Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 24 Middle East and Africa Uterine Cancer Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Bristol-Myers Squibb Company: Overview
Table 26 Bristol-Myers Squibb Company: Product Portfolio
Table 27 Bristol-Myers Squibb Company: Key Developments
Table 28 Pfizer Inc.: Overview
Table 29 Pfizer Inc.: Product Portfolio
Table 30 Pfizer Inc.: Key Developments
Table 31 Janssen Pharmaceuticals (Johnson & Johnson): Overview
Table 32 Janssen Pharmaceuticals (Johnson & Johnson): Product Portfolio
Table 33 Janssen Pharmaceuticals (Johnson & Johnson): Key Developments
Table 34 F. Hoffmann-La Roche Ltd: Overview
Table 35 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 36 F. Hoffmann-La Roche Ltd: Key Developments
Table 37 Sanofi: Overview
Table 38 Sanofi: Product Portfolio
Table 39 Sanofi: Key Developments
Table 40 Eli Lilly Services Inc: Overview
Table 41 Eli Lilly Services Inc: Product Portfolio
Table 42 Eli Lilly Services Inc: Key Developments
Table 43 Novartis AG: Overview
Table 44 Novartis AG: Product Portfolio
Table 45 Novartis AG: Key Developments
Table 46 AstraZeneca: Overview
Table 47 AstraZeneca: Product Portfolio
Table 48 AstraZeneca: Key Developments
Table 49 Eisai Inc.: Overview
Table 50 Eisai Inc.: Product Portfolio
Table 51 Eisai Inc.: Key Developments
Table 52 GSK Plc: Overview
Table 53 GSK Plc: Product Portfolio
Table 54 GSK Plc: Key Developments
Table 55 Merck & Co., Inc.: Overview
Table 56 Merck & Co., Inc.: Product Portfolio
Table 57 Merck & Co., Inc.: Key Developments
Table 58 Antiva Biosciences: Overview
Table 59 Antiva Biosciences: Product Portfolio
Table 60 Antiva Biosciences: Key Developments
Table 61 Eisai Co., Ltd.: Overview
Table 62 Eisai Co., Ltd.: Product Portfolio
Table 63 Eisai Co., Ltd.: Key Developments
Table 64 Kineta: Overview
Table 65 Kineta: Product Portfolio
Table 66 Kineta: Key Developments
Table 67 IMMVIRA CO., LTD: Overview
Table 68 IMMVIRA CO., LTD: Product Portfolio
Table 69 IMMVIRA CO., LTD: Key Developments
Table 70 Shanghai Henlius Biotech, Inc.: Overview
Table 71 Shanghai Henlius Biotech, Inc.: Product Portfolio
Table 72 Shanghai Henlius Biotech, Inc.: Key Developments
Table 73 Iovance Biotherapeutics, Inc.: Overview
Table 74 Iovance Biotherapeutics, Inc.: Product Portfolio
Table 75 Iovance Biotherapeutics, Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 3 Global Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 4 Global Uterine Cancer Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 5 Global Uterine Cancer Treatment Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 6 Endometrial Cancer Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 7 Uterine Sarcoma Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Global Uterine Cancer Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 9 Chemotherapy Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Hormone Therapy Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 11 Targeted Therapy Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Immunotherapy Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Radiation Therapy Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Surgery Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Other Treatment Types in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Uterine Cancer Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 17 North America Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 North America Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 19 North America Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 20 North America Uterine Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 21 South America Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 22 South America Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 23 South America Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 24 South America Uterine Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 25 Europe Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 26 Europe Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 27 Europe Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 28 Europe Uterine Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 29 Asia-Pacific Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 30 Asia-Pacific Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 31 Asia-Pacific Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 32 Asia-Pacific Uterine Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 33 Middle East and Africa Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 34 Middle East and Africa Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 35 Middle East and Africa Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 36 Bristol-Myers Squibb Company: Financials
Figure 37 Pfizer Inc.: Financials
Figure 38 Janssen Pharmaceuticals (Johnson & Johnson): Financials
Figure 39 F. Hoffmann-La Roche Ltd: Financials
Figure 40 Sanofi: Financials
Figure 41 Eli Lilly Services Inc: Financials
Figure 42 Novartis AG: Financials
Figure 43 AstraZeneca: Financials
Figure 44 Eisai Inc.: Financials
Figure 45 GSK Plc: Financials
Figure 46 Merck & Co., Inc.: Financials
Figure 47 Antiva Biosciences: Financials
Figure 48 Eisai Co., Ltd.: Financials
Figure 49 Kineta: Financials
Figure 50 IMMVIRA CO., LTD: Financials
Figure 51 Shanghai Henlius Biotech, Inc.: Financials
Figure 52 Iovance Biotherapeutics, Inc. Financials
Figure 1 Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 3 Global Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 4 Global Uterine Cancer Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 5 Global Uterine Cancer Treatment Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 6 Endometrial Cancer Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 7 Uterine Sarcoma Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Global Uterine Cancer Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 9 Chemotherapy Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Hormone Therapy Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 11 Targeted Therapy Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Immunotherapy Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Radiation Therapy Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Surgery Treatment Type in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 15 Other Treatment Types in Global Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Uterine Cancer Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 17 North America Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 18 North America Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 19 North America Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 20 North America Uterine Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 21 South America Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 22 South America Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 23 South America Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 24 South America Uterine Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 25 Europe Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 26 Europe Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 27 Europe Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 28 Europe Uterine Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 29 Asia-Pacific Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 30 Asia-Pacific Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 31 Asia-Pacific Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 32 Asia-Pacific Uterine Cancer Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 33 Middle East and Africa Uterine Cancer Treatment Market Value, 2022-2033 (US$ Billion)
Figure 34 Middle East and Africa Uterine Cancer Treatment Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 35 Middle East and Africa Uterine Cancer Treatment Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 36 Bristol-Myers Squibb Company: Financials
Figure 37 Pfizer Inc.: Financials
Figure 38 Janssen Pharmaceuticals (Johnson & Johnson): Financials
Figure 39 F. Hoffmann-La Roche Ltd: Financials
Figure 40 Sanofi: Financials
Figure 41 Eli Lilly Services Inc: Financials
Figure 42 Novartis AG: Financials
Figure 43 AstraZeneca: Financials
Figure 44 Eisai Inc.: Financials
Figure 45 GSK Plc: Financials
Figure 46 Merck & Co., Inc.: Financials
Figure 47 Antiva Biosciences: Financials
Figure 48 Eisai Co., Ltd.: Financials
Figure 49 Kineta: Financials
Figure 50 IMMVIRA CO., LTD: Financials
Figure 51 Shanghai Henlius Biotech, Inc.: Financials
Figure 52 Iovance Biotherapeutics, Inc. Financials
